Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Date
2019-08-27
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Citation
CREDENCE Study Investigators 2019, 'Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial', Circulation, vol. 140, no. 9, pp. 739-750. https://doi.org/10.1161/CIRCULATIONAHA.119.042007